-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written | Edited by Wang Cong | Typesetting by Wang Duoyu | Shui Chengwen With the widespread use of mRNA new crown vaccines around the world, mRNA technology has demonstrated powerful capabilities
.
In addition to the marketed mRNA types, there are several novel mRNAs that are undergoing clinical trials or preclinical studies and have demonstrated potential effects
.
Among them, self-amplifying RNA vaccines (saRNA) have attracted widespread attention as a new generation of mRNA.
Compared with traditional mRNA vaccines, the new saRNA vaccines add replicable sequences to the delivered mRNA sequences, which can act like viruses after entering cells.
In the same way, it can use host cells for self-replication, so as to achieve high expression of antigens and generate strong immune responses at extremely low injection doses (a fraction to several tenths of the conventional mRNA vaccine dose).
ability
.
This ultra-low injection dose has three important advantages: 1.
It has greater manufacturing potential, and the same origin and production equipment can produce more vaccines; 2.
Because of the low dose, it reduces the risk of side effects; 3.
The low-dose feature can be used in combination with other vaccines
.
Comparison of traditional mRNA vaccines and saRNA vaccines Among them, the self-amplifying RNA vaccine ARCT-154 developed by Arcturus Therapeutics has the fastest progress.
It started Phase 1 clinical trials in the summer of 2020 and is currently in Phase 3 clinical trials
.
On April 20, 2022, Arcturus Therapeutics announced the results of its Phase 3 clinical trial of its self-amplifying RNA new crown vaccine.
In this Phase 3 clinical trial in Vietnam, a total of more than 17,000 people who had not been vaccinated against the new crown vaccine were killed.
Randomly assigned to two groups, the experimental group received two doses of ARCT-154 vaccine of 5 micrograms each, and the control group received two doses of equal placebo
.
During this phase 3 clinical trial, it was confirmed that Vietnam has transitioned from the Delta mutant to the Omicron mutant.
The test results showed that the self-amplifying RNA new crown vaccine has a protective effect of 55% against symptomatic new coronary pneumonia, and the protective effect against severe and death is 55%.
95.
3%
.
There were 9 new crown-related deaths in the control group, only 1 in the experimental group, 41 people in the control group had severe new crowns, and only 2 people in the experimental group had severe new crowns
.
In the mRNA vaccine space, Moderna and Pfizer/BioNTech are leading the charge, and they are also aggressively pushing for booster programs
.
In the face of the competition between these two mRNA vaccines, Arcturus Therapeutics is trying to get a piece of the pie by using a differentiated self-amplifying RNA vaccine as a booster vaccination, but it is doubtful whether the vaccine can be finally approved
.
Arcturus R&D pipeline Arcturus Therapeutics currently has a total of 5 R&D pipelines.
In addition to the two new crown vaccine pipelines, there is also an influenza mRNA vaccine, as well as ornithine carbamoyltransferase deficiency (OTCD) and cystic fibrosis (CF).
mRNA therapy for a genetic disease
.
Reference: https://ir.
arcturusrx.
com/news-releases/news-release-details/arcturus-announces-self-amplifying-covid-19-mrna-vaccine open reprint welcome to the circle of friends and WeChat group